Viemed Healthcare, Inc.
VMD Nasdaq· Services-Misc Health & Allied Services, Nec
Last close · Oct 27, 2026
$9.68
KIRA · Stoqly’s AI analyst, in plain words
- Viemed Healthcare, Inc. had $270M of revenue in fiscal 2025, up 20.5% on the year before. Over five years, revenue changed +15.5% a year on average.
- Its operating margin was 8.5%, up 0.5 pts: of every 100 in sales, about 8 is left after running the business.
- Viemed Healthcare, Inc. made $14.9M of net profit in fiscal 2025. From fiscal 2018 to 2025, diluted EPS grew 6.4% a year.
- Free cash flow was $11.9M in fiscal 2025, 4.4% of revenue.
- Viemed Healthcare, Inc. returned $13.2M to shareholders in fiscal 2025, 111% of free cash flow. The diluted share count rose 0.0%.
- Viemed Healthcare, Inc. has $1.1M more cash than debt.
Market cap
$398M
P/E
26.9x
Revenue
$270M
Net income
$14.9M
Free cash flow
$11.9M
Operating margin
8.5%
Viemed Healthcare, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+20.5%
Yes. Sales grew 20.5% last year.
Does it make a profit?
5.5%
A little. It keeps 5.5% of every sale as profit.
Does profit turn into cash?
4.4%
Partly. 4.4% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
26.9x
One share costs 26.9 times its yearly profit per share.
What Viemed Healthcare, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- VIEMED HEALTHCARE, INC.
- CIK
- 0001729149
Viemed Healthcare, Inc. · VMD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $117M | $139M | $183M | $224M | $270M |
| Revenue growth | −10.9% | 18.6% | 31.8% | 22.5% | 20.5% |
| Gross margin | 62.7% | 61.0% | 61.6% | 59.4% | 57.5% |
| Operating margin | 9.9% | 5.9% | 7.8% | 8.0% | 8.5% |
| Net income | $9.1M | $6.2M | $10.2M | $11.3M | $14.9M |
| Net margin | 7.8% | 4.5% | 5.6% | 5.0% | 5.5% |
| Diluted EPS | $0.22 | $0.16 | $0.25 | $0.28 | $0.37 |
| Cash | |||||
| Cash from operations | $22.5M | $27.7M | $45.2M | $39.1M | $51.9M |
| Capital expenditure | $19.7M | $22.9M | $26.1M | $37.8M | $40.0M |
| Free cash flow | $2.8M | $4.9M | $19.1M | $1.3M | $11.9M |
| FCF margin | 2.4% | 3.5% | 10.4% | 0.6% | 4.4% |
| Share buybacks | $0.0M | $9.6M | $0.0M | $0.0M | $13.2M |
| Share count change | 0.4% | −2.1% | 1.4% | 1.1% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $28.4M | $16.9M | $12.8M | $17.5M | $13.5M |
| Debt incl. finance leases | $5.8M | $0.0M | $7.1M | $4.0M | $12.4M |
| Shareholders' equity | $94.8M | $97.1M | $114M | $131M | $142M |
| Net debt / EBITDA | −1.0x | −0.7x | −0.2x | −0.3x | −0.0x |
| Current ratio | 2.7x | 2.1x | 1.2x | 1.4x | 1.2x |
| Returns and quality | |||||
| Return on capital | 11.7% | 7.1% | 9.4% | 10.7% | 11.5% |
| Return on equity | 10.3% | 6.5% | 9.7% | 9.2% | 10.9% |
| Return on tangible equity | 9.6% | 6.4% | 12.3% | 11.5% | 18.4% |
| Piotroski F-score | 6 | 6 | 5 | 6 | 5 |
| Altman Z'' | 8.6 | 8.7 | 5.5 | 6.1 | 5.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.6M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Viemed Healthcare, Inc. · VMD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.68 a share, the company is worth $398M: 26.9 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001729149). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.